Skip to content

Lyon PJI Retrospective Cohort Study

Lyon Prosthetic Joint Infection Retrospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04722926
Enrollment
400
Registered
2021-01-25
Start date
2022-01-10
Completion date
2024-03-01
Last updated
2022-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Joint Infection

Keywords

prosthesis joint infection, relapse

Brief summary

Bone and joint infections (BJI), although infrequent (prevalence of 70 per 100,000 in France), have a significant economic and clinical impact. Between 2008 and 2013, the prevalence of BJI increased and infections involving joint prosthesis (PJI) represent a third of BJI in France. They are most often post-operative and more expensive than native IOAs. This study aims to describe PJI and understand the failure mechanisms of PJI in order to improve their management.

Interventions

OTHERPJI

patients having had a PJI managed at the CRIOAc Lyon, with or without relapse

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* patients having had a PJI between 2018 and 2020

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
description of surgical treatmentbetween 2018 and 2020type of surgery: 1-step exchange, 2- step exchange, DAIR
description of antibiotic usedbetween 2018 and 2020type of antibiotic : name
description of antibiotic treatmentbetween 2018 and 2020duration of antibiotic treatment
rate of PJIbetween 2018 and 2020proportion of PJI among all BJI
Description of PJIbetween 2018 and 2020acute/chronic
Description of type of prosthesis PJIbetween 2018 and 2020number of prosthesis
Description of patients having had a PJIbetween 2018 and 2020type of patients: age
Description of comorbidities of patients having had a PJIbetween 2018 and 2020type of comorbidities..
rate of bacteriabetween 2018 and 2020epidemiologic description of PJI

Secondary

MeasureTime frameDescription
description of the failurebetween 2018 and 2020type of failure : persistence or surinfection and management of failure
rate of failurebetween 2018 and 2020proportion of patients having a failure

Countries

France

Contacts

Primary ContactEugenie Mabrut, CRA
eugenie.mabrut@chu-lyon.fr. 04 26 73 29 38
Backup ContactTristan Ferry, MD,PhD
tristan.ferry@chu-lyon.fr. 04 26 73 29 38

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026